NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial

8.5
Average: 8.5 (2 votes)
Langenbecks Arch Surg. 2002 Mar;386(8):570-4. Epub 2002 Feb 13.Related Articles, Links NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, Cammerer G, Leder G, Beger HG. Department of General Surgery, University of Ulm, Germany. [b]BACKGROUND:[/b] NSC-631570 (Ukrain) is a semisynthetic compound of thiophosphoric acid and the alkaloid chelidonine from the plant Chelidonium majus. It has been used in complementary herbal medicine for more than 20 years for the treatment of benign and malignant tumors. [b]PATIENTS/METHODS:[/b] Between August 1999 and June 2001, 90 patients with histologically proven unresectable [url=http://en.wikipedia.org/wiki/pancreatic_cancer]pancreatic cancer[/url] were randomized in a monocentric, controlled, randomized study. Patients in arm A received 1000 mg gemcitabine/m2, those in arm B received 20 mg NSC-631570, and those in arm C received 1000 mg gemcitabine/m2 followed by 20 mg NSC-631570 weekly. End point of the study was overall survival. [b]RESULTS:[/b] In all three arms therapy was well tolerated and toxicity was moderate. At the first re-evaluation in arm A 32%, in arm B 75%, and in arm C 82% showed no change or partial remission according to WHO criteria (arm A versus arm B: Phttp://en.wikipedia.org/wiki/Kaplan-Meier_estimator]Kaplan-Meier analysis[/url] was in arm A 5.2 months, in arm B 7.9 months, and in arm C 10.4 months (arm A versus arm B: P